Study guide

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries

Key Takeaways Explain This Topic AI

Active pulmonary TB is treated for 6 months: rifampicin, isoniazid, pyrazinamide and ethambutol for 2 months, then rifampicin and isoniazid for 4 months, with pyridoxine (NICE NG33).

Rifampicin is an enzyme inducer that turns secretions orange and reduces the effectiveness of hormonal contraception; ethambutol can cause optic neuritis.

People with HIV are offered antiretroviral therapy at diagnosis regardless of CD4 count, and an undetectable viral load means HIV is not transmitted sexually (U=U).

HIV post-exposure prophylaxis is started as soon as possible after a significant exposure, ideally within 24 hours and no later than 72 hours, and continued for 28 days.

Hepatitis B surface antigen indicates current infection; anti-HBs alone indicates vaccine immunity, while anti-HBs with anti-HBc indicates immunity from past infection.

Last updated: October 2026

  • Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries
  • Tuberculosis (TB)

Mycobacterium tuberculosis spreads by airborne droplets. Most infected people develop latent TB infection ; reactivation risk is higher with HIV, diabetes, CKD, malnutrition, alcohol misuse and immunosuppression (especially anti-TNF biologics and corticosteroids).

Active TB

Pulmonary: cough for more than 3 weeks , haemoptysis, fever, night sweats, weight loss ; chest X-ray may show upper lobe consolidation or cavitation and hilar nodes. Higher-risk groups include people born in high-incidence countries, homeless people, prisoners and people who use drugs.

Extrapulmonary: lymph nodes (the commonest), pleura, spine (Pott's disease) , meninges, genitourinary tract, abdomen and miliary disease.

Investigations: 3 sputum samples (including one early-morning sample) for smear microscopy (acid-fast bacilli) , culture (the gold standard, taking weeks) and rapid nucleic acid amplification testing for TB and rifampicin resistance ; tissue samples for extrapulmonary disease; HIV testing for everyone with TB.

Treatment (NICE NG33)

  • Phase Drugs Duration
  • Initial R ifampicin, I soniazid, P yrazinamide, E thambutol 2 months
  • Continuation Rifampicin and isoniazid 4 months (longer for CNS TB, usually 10 months, with corticosteroids)

Pyridoxine is given with isoniazid to prevent peripheral neuropathy. Check liver function, renal function and visual acuity at baseline.

Drug Key Adverse Effects

Rifampicin Orange urine and tears , hepatitis, potent enzyme inducer (reduces hormonal contraception, warfarin and other drug levels)

  • Isoniazid Peripheral neuropathy , hepatitis
  • Pyrazinamide Hepatitis, raised urate and gout , arthralgia
  • Ethambutol Optic neuritis (reduced acuity and colour vision); adjust in renal impairment

Public health: TB is notifiable . People with infectious pulmonary TB are isolated (respiratory precautions) until they have had about 2 weeks of effective treatment; contacts are traced and screened. Directly observed therapy supports people at risk of poor adherence. Drug-resistant TB needs specialist care.

Latent TB & BCG

Latent infection is diagnosed with an interferon-gamma release assay (or Mantoux test) in contacts, migrants from high-incidence countries and people before biologic therapy . Treatment options include 3 months of rifampicin and isoniazid or 6 months of isoniazid . BCG vaccination is offered to babies at higher risk (living in areas with a high TB incidence or with a parent or grandparent from a high-incidence country).

HIV

Testing (BHIVA): test anyone with an indicator condition (for example TB, pneumonia, lymphoma, hepatitis B or C, unexplained weight loss, a sexually transmitted infection, shingles in a young person), in sexual health and antenatal services, and widely in areas of high prevalence (including opt-out testing in some emergency departments).

Primary HIV infection (seroconversion): 2–6 weeks after exposure, a glandular fever-like illness with fever, sore throat, rash, lymphadenopathy and mouth ulcers. A fourth-generation test (antibody plus p24 antigen) may need repeating.

Advanced HIV: opportunistic infections at low CD4 counts, such as Pneumocystis pneumonia (below 200 cells/mm³; co-trimoxazole prophylaxis), toxoplasmosis and cryptococcal meningitis (below 100), and cytomegalovirus retinitis (below 50).

Treatment: antiretroviral therapy (ART) for everyone diagnosed , regardless of CD4 count. Effective ART with an undetectable viral load gives near-normal life expectancy and no sexual transmission (U=U) .

Pregnancy: universal antenatal screening; ART to suppress the viral load; vaginal birth is possible if the viral load is undetectable; the baby receives post-exposure prophylaxis; formula feeding is advised in the UK, with specialist support for mothers with an undetectable viral load who choose to breastfeed.

Prevention: condoms, pre-exposure prophylaxis (PrEP , tenofovir with emtricitabine) for people at higher risk, and post-exposure prophylaxis (PEP) : a 28-day course of combination ART, started as soon as possible, ideally within 24 hours and no later than 72 hours .

Confidentiality and partner notification are discussed in section 15.3.

  • Hepatitis B & C
  • Hepatitis B Serology
  • Marker Meaning
  • HBsAg Current infection (chronic if present for more than 6 months)
  • Anti-HBc IgM Acute infection
  • Anti-HBc (total/IgG) Past or current exposure to the virus
  • Anti-HBs Immunity : alone after vaccination ; with anti-HBc after past infection
  • HBeAg / HBV DNA High viral replication and infectivity

Hepatitis B is spread by blood, sexual contact and from mother to baby . Babies of mothers with hepatitis B receive vaccine at birth (plus hepatitis B immunoglobulin if the mother is highly infectious) and complete the schedule. Chronic infection may need tenofovir or entecavir and needs surveillance for cirrhosis and hepatocellular carcinoma . Vaccination is part of the infant schedule and is offered to healthcare workers and other at-risk groups.

Hepatitis C

Usually spread through injecting drug use , contaminated medical equipment, blood products before 1991 or tattoos in unregulated settings; sexual transmission is less common. Most infections become chronic and are often asymptomatic until cirrhosis develops. Test with HCV antibody , then HCV RNA to confirm current infection. Direct-acting antivirals for 8–12 weeks cure over 95% of patients. There is no vaccine .

Needlestick & Other Occupational Exposures

First aid: encourage the wound to bleed (do not suck or scrub), wash with soap and running water , and irrigate splashes to the eyes or mouth with water.

Report immediately to occupational health or the emergency department (out of hours) and complete an incident report.

Risk assessment: type of exposure (a deep injury with a hollow needle containing blood is highest risk) and the source patient's status. With consent , test the source for HIV, hepatitis B and hepatitis C. A source who lacks capacity can be tested only if it is in their best interests, not solely for the benefit of the injured worker.

Approximate transmission risk after percutaneous exposure: hepatitis B up to about 30% (if the source is HBeAg-positive and the worker is not immune), hepatitis C about 0.5–2%, HIV about 0.3%.

Post-exposure measures: HIV PEP started as soon as possible (ideally within an hour or two) if the exposure is significant and the source is HIV-positive with a detectable or unknown viral load; hepatitis B vaccine booster or course, with or without hepatitis B immunoglobulin , depending on the worker's immunity and the source; no PEP exists for hepatitis C , so the worker has follow-up testing and early treatment if infected.

Follow-up: baseline and later blood tests; safer sex and avoiding blood donation until follow-up testing is complete.

Loading diagram...